Howell SJ, Casbard A, Carucci M, Ingarfield K, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded bi Lancet Oncol 2022 Jun 1. pii: S1470-2045(22)00284.
PMID: 35671774